Galactose Functionalized Mesoporous Silica Nanoparticles As Delivery Vehicle in the Treatment of Hepatitis C Infection.
Mousumi Beto MukherjeeRanajoy MullickB Uma ReddySaumitra DasAshok M RaichurPublished in: ACS applied bio materials (2020)
DNA and RNA based antiviral strategies using nonviral vectors have shown better potential over the viral pathway due to the fewer chances of gene recombination and immunogenicity. In this work a mesoporous silica nanoparticle (MSN) based carrier system has been used for targeted delivery of shDNA molecule against the conserved 5'-untranslated region (UTR) in the RNA of a hepatitis C virus to inhibit its replication. The MSNs coated with amine and galactose could specifically target liver cells. Significant reduction (about 94%) of viral RNA level was achieved in HCV-JFH1 infectious cell culture compared to the control RNA levels directed the successful delivery and action of the shDNA. This study showed that Gal-AMSN can be used as a synthetic delivery vector to deliver the shDNA effectively for the treatment of HCV infection.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- nucleic acid
- sars cov
- induced apoptosis
- dna methylation
- climate change
- single molecule
- combination therapy
- oxidative stress
- cell free
- mass spectrometry
- dna repair
- copy number
- human health
- risk assessment
- hiv infected
- liquid chromatography
- genome wide identification
- circulating tumor cells
- pi k akt
- iron oxide